Erratum to Inhibition of FAAH reduces nitroglycerin-induced migraine-like pain and trigeminal neuronal hyperactivity in mice [Eur. Neuropsychopharmacol., (2015), 25, 1388-1396] Doi: 10.1016/j.euroneuro.2015.04.001;Inhibition of FAAH reduces nitroglycerin-induced migraine-like pain and trigeminal neuronal hyperactivity in mice

European Neuropsychopharmacology

Volumn 25, Issue 8, 2015, Pages 1388-1396

  Nozaki, Chihiro ^a   Markert, Astrid ^a   Zimmer, Andreas ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

CB1 receptor; Endocannabinoid; FAAH; Headache; Migraine; Nitroglycerin

Indexed keywords

CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; FATTY ACID AMIDASE INHIBITOR; PF 3845; RIMONABANT; UNCLASSIFIED DRUG; ACYLGLYCEROL LIPASE; AMIDASE; AMIDE; ANALGESIC AGENT; ANANDAMIDE; ARACHIDONIC ACID DERIVATIVE; BENZAMIDE DERIVATIVE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CARBAMIC ACID DERIVATIVE; CNR1 PROTEIN, MOUSE; CNR2 PROTEIN, MOUSE; CYCLOHEXYL CARBAMIC ACID 3'-CARBAMOYLBIPHENYL-3-YL ESTER; ENDOCANNABINOID; ENZYME INHIBITOR; FATTY-ACID AMIDE HYDROLASE; GLYCERYL TRINITRATE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ACUTE DRUG ADMINISTRATION; ANALGESIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; GENE DELETION; IMMUNOHISTOCHEMISTRY; MALE; MECHANICAL HYPERALGESIA; MIGRAINE; MOUSE; NONHUMAN; ONCOGENE C FOS; PAIN THRESHOLD; PREMEDICATION; PRIORITY JOURNAL; TRIGEMINAL NUCLEUS; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; GENETICS; HYPERALGESIA; KNOCKOUT MOUSE; METABOLISM; MIGRAINE DISORDERS; PAIN MEASUREMENT; PATHOPHYSIOLOGY; TOUCH;

AMIDOHYDROLASES; ANALGESICS; ANIMALS; ARACHIDONIC ACIDS; BENZAMIDES; CANNABINOID RECEPTOR ANTAGONISTS; CARBAMATES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCANNABINOIDS; ENZYME INHIBITORS; HYPERALGESIA; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIGRAINE DISORDERS; MONOACYLGLYCEROL LIPASES; NITROGLYCERIN; PAIN MEASUREMENT; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; TOUCH; TRIGEMINAL NUCLEI;

EID: 84938740006     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2015.09.001     Document Type: Erratum

References (31)

1. Ahn K., Johnson D.S., Cravatt B.F. Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders. Expert Opin. Drug Discov. 2009, 4:763-784.
2. Ahn K., Johnson D.S., Mileni M., Beidler D., Long J.Z., McKinney M.K., Weerapana E., Sadagopan N., Liimatta M., Smith S.E., Lazerwith S., Stiff C., Kamtekar S., Bhattacharya K., Zhang Y., Swaney S., Van Becelaere K., Stevens R.C., Cravatt B.F. Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem. Biol. 2009, 16:411-420.
3. Akerman S., Holland P.R., Goadsby P.J. Diencephalic and brainstem mechanisms in migraine. Nat. Rev. Neurosci. 2011, 12:570-584.
4. Akerman S., Holland P.R., Lasalandra M.P., Goadsby P.J. Endocannabinoids in the brainstem modulate dural trigeminovascular nociceptive traffic via CB1 and "triptan" receptors: implications in migraine. J. Neurosci. 2013, 33:14869-14877.
5. Bates E.A., Nikai T., Brennan K.C., Fu Y.H., Charles A.C., Basbaum A.I., Ptacek L.J., Ahn A.H. Sumatriptan alleviates nitroglycerin-induced mechanical and thermal allodynia in mice. Cephalalgia 2010, 30:170-178.
6. Bilkei-Gorzo A., Racz I., Michel K., Mauer D., Zimmer A., Klingmuller D. Control of hormonal stress reactivity by the endogenous opioid system. Psychoneuroendocrinology 2008, 33:425-436.
7. Booker L., Kinsey S.G., Abdullah R.A., Blankman J.L., Long J.Z., Ezzili C., Boger D.L., Cravatt B.F., Lichtman A.H. The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice. Br. J. Pharmacol. 2012, 165:2485-2496.
8. Buckley N.E., McCoy K.L., Mezey E., Bonner T., Zimmer A., Felder C.C., Glass M. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur. J. Pharmacol. 2000, 396:141-149.
9. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., Yaksh T.L. Quantitative assessment of tactile allodynia in the rat paw. J. Neurosci. Methods 1994, 53:55-63.
10. Clapper J.R., Moreno-Sanz G., Russo R., Guijarro A., Vacondio F., Duranti A., Tontini A., Sanchini S., Sciolino N.R., Spradley J.M., Hohmann A.G., Calignano A., Mor M., Tarzia G., Piomelli D. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat. Neurosci. 2010, 13:1265-1270.
11. Cravatt B.F., Demarest K., Patricelli M.P., Bracey M.H., Giang D.K., Martin B.R., Lichtman A.H. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. USA 2001, 98:9371-9376.
12. Cupini L.M., Costa C., Sarchielli P., Bari M., Battista N., Eusebi P., Calabresi P., Maccarrone M. Degradation of endocannabinoids in chronic migraine and medication overuse headache. Neurobiol. Dis. 2008, 30:186-189.
13. Di Marzo V., Melck D., Bisogno T., De Petrocellis L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. 1998, 21:521-528.
14. Dinh T.P., Carpenter D., Leslie F.M., Freund T.F., Katona I., Sensi S.L., Kathuria S., Piomelli D. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. USA 2002, 99:10819-10824.
15. Greco R., Gasperi V., Maccarrone M., Tassorelli C. The endocannabinoid system and migraine. Exp. Neurol. 2010, 224:85-91.
16. Jayamanne A., Greenwood R., Mitchell V.A., Aslan S., Piomelli D., Vaughan C.W. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br. J. Pharmacol. 2006, 147:281-288.
17. Kazemi H., Rahgozar M., Speckmann E.J., Gorji A. Effect of cannabinoid receptor activation on spreading depression. Iran. J. Basic Med. Sci. 2012, 15:926-936.
18. Kinsey S.G., Long J.Z., Cravatt B.F., Lichtman A.H. Fatty acid amide hydrolase and monoacylglycerol lipase inhibitors produce anti-allodynic effects in mice through distinct cannabinoid receptor mechanisms. J. Pain 2010, 11:1420-1428.
19. Makara J.K., Mor M., Fegley D., Szabo S.I., Kathuria S., Astarita G., Duranti A., Tontini A., Tarzia G., Rivara S., Freund T.F., Piomelli D. Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat. Neurosci. 2005, 8:1139-1141.
20. Murillo-Rodriguez E., Vazquez E., Millan-Aldaco D., Palomero-Rivero M., Drucker-Colin R. Effects of the fatty acid amide hydrolase inhibitor URB597 on the sleep-wake cycle, c-Fos expression and dopamine levels of the rat. Eur. J. Pharmacol. 2007, 562:82-91.
21. Pertwee R.G. Cannabinoid receptors and pain. Prog. Neurobiol. 2001, 63:569-611.
22. Rossi C., Pini L.A., Cupini M.L., Calabresi P., Sarchielli P. Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: relation with serotonin levels. Eur. J. Clin. Pharmacol. 2008, 64:1-8.
23. Russell M.B. Headache: Medication overuse headache--seeking a management consensus. Nat. Rev. Neurol. 2014, 10:309-310.
24. Russo E. Cannabis for migraine treatment: the once and future prescription? An historical and scientific review. Pain 1998, 76:3-8.
25. Russo E.B. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?. Neuro Endocrinol. Lett. 2004, 25:31-39.
26. Russo R., Loverme J., La Rana G., Compton T.R., Parrott J., Duranti A., Tontini A., Mor M., Tarzia G., Calignano A., Piomelli D. The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3[U+05F3]-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J. Pharmacol. Exp. Ther. 2007, 322:236-242.
27. Schlosburg J.E., Blankman J.L., Long J.Z., Nomura D.K., Pan B., Kinsey S.G., Nguyen P.T., Ramesh D., Booker L., Burston J.J., Thomas E.A., Selley D.E., Sim-Selley L.J., Liu Q.S., Lichtman A.H., Cravatt B.F. Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat. Neurosci. 2010, 13:1113-1119.
28. Smith S.C., Wagner M.S. Clinical endocannabinoid deficiency (CECD) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?. Neuro Endocrinol. Lett. 2014, 35:198-201.
29. Soria-Gomez E., Matias I., Rueda-Orozco P.E., Cisneros M., Petrosino S., Navarro L., Di Marzo V., Prospero-Garcia O. Pharmacological enhancement of the endocannabinoid system in the nucleus accumbens shell stimulates food intake and increases c-Fos expression in the hypothalamus. Br. J. Pharmacol. 2007, 151:1109-1116.
30. Wenzel D., Matthey M., Bindila L., Lerner R., Lutz B., Zimmer A., Fleischmann B.K. Endocannabinoid anandamide mediates hypoxic pulmonary vasoconstriction. Proc. Natl. Acad. Sci. USA 2013, 110:18710-18715.
31. Zimmer A., Zimmer A.M., Hohmann A.G., Herkenham M., Bonner T.I. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. Sci. USA 1999, 96:5780-5785.